Pharmaceuticals, Biotechnology and Life Sciences
The 16th annual BIO-Europe Spring global life sciences partnering event will be held March 28–31, 2022 in a fully digital…
Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) have announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.
Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in…
Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, has closed a Series A financing of ~$31 million (€28 million).
Medexprim has appointed Alexandre Blanchot as Business Development Manager.
Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
The New England Journal of Medicine (NEJM) published data showing the Phase III MONALEESA-2 trial for NovartIs’s Kisqali (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival.
Thermo Fisher Scientific and Servier’s affiliate Symphogen have announced the continuation of their collaboration to provide biopharmaceutical discovery and development…
Novo Nordisk has expanded its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
MiGenTra and ProBioGen have announced the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to…